Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,

Diagnostic 95

Diagnostic Radiation Oncology Radiation Clinic 95

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We

Diagnose 52

Diagnose Diagnostic Disease Radiation 52